Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNS in CRF
NCT00892892Phase 4Withdrawn
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Start
- Nov 2009
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of Rilmenidine in chronic kidney disease (CKD) and hypertension (HTN) (2 arms), sponsored by FAU Erlangen-Nürnberg Medical Faculty. Primary endpoint: Sympathetic activation for the development and progression of chronic renal failure at 3 months. Planned start Nov 2009; status: withdrawn.
02
Drugs
Rilmenidine
03
Conditions
chronic kidney disease (CKD)hypertension (HTN)
Beyond the preview
Go deeper on NCT00892892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00892892.